The simultaneous inhibition of G-protein-coupled receptors has been suggested as a therapy alternative for adult FSGS patients (ANGII and CCR2), and a Phase 3 randomized trial (NCT05183646) is currently recruiting. Here, CCR2 is linked to focal segmental glomerulosclerosis.